Panton-Valentine Leukocidinproducing Staphylococcus aureus

To the Editor: Panton-Valentine leukocidin (PVL) is a cytotoxin produced by Staphylococcus aureus that causes leukocyte destruction and tissue necrosis (1). Although produced by <5% of S. aureus strains, the toxin is detected in large percentages of isolates that cause necrotic skin lesions and severe necrotizing pneumonia (2). Although commonly associated with community-acquired methicillinresistant S. aureus (CA-MRSA) (3), several outbreaks due to methicillinsusceptible S. aureus (MSSA) have also been reported (4-6). We describe an outbreak of cutaneous infections caused by PVL-producing MSSA that affected 6 of 11 members of 2 related families.

During a period of 6 months, a cluster of *S. aureus* skin and soft tissue infections occurred in 2 families in Jerusalem, Israel, that were related through the mothers, who are sisters. The event started with the 4-year-old boy of family A, who had 5 episodes of skin infections, including 2 episodes of perianal abscesses that required drainage and hospitalization. Culture of pus grew MSSA that was resistant to erythromycin and clin-

damycin. Subsequently, recurrent abscesses and cellulitis developed in the boy's father's legs, and his mother had severe periorbital cellulitis that required hospitalization and surgical drainage. Approximately 1 month later, a 9-year-old boy in family B had severe cellulitis and abscess around his knee that required hospitalization and surgical drainage. Subsequently, infections developed in 2 more children in family B: 1 had a finger pulpspace infection and the other cellulitis of the lower abdomen. All pus cultures grew S. aureus with identical susceptibility patterns. The cases are summarized in the Table.

Following these events, the families consulted the infectious diseases at the Hadassah-Hebrew clinic Medical Center University in Jerusalem. Since the clinical isolates were not available, nasal cultures were obtained from all family members. S. aureus was isolated from all the affected members of family A and from the parents and the 2 boys in family B. All 7 isolates were subjected to pulsed-field gel electrophoresis (PFGE) after digestion with SmaI. All except 1 had identical band patterns and the same antimicrobial drug susceptibilities as the clinical isolates. The presence of PVL genes was examined by PCR as previously described (2) and was detected only in the isolates with identical PFGE patterns. The families were advised to apply mupirocin nasal ointment twice a day for 5 days and to bathe with 4% chlorhexidine scrub for 1 week (7). At 7 months of follow-up, no new cases of skin infection had occurred in either family. An epidemiologic investigation was undertaken by the local department of health to determine if 3 kindergartens and 2 schools attended by the 7 children had an increased incidence of staphylococcal skin disease. No evidence of unusual disease was found.

We describe here the first confirmed cases of PVL-producing S. aureus infections in Israel. Maier et al (8) recently described 2 cases of similar infections that occurred in German tourists after visiting the Dead Sea area, but since these infections were caused by MRSA, it is probable that the isolates were genetically distinct from the strain described here. In addition, to the best of our knowledge this is the first description of transmission of PVL-producing MSSA between related families. Previous reports described community-related outbreaks that occurred within families (6,8,9), between schoolmates (4), and between football team players (10). The exact route of transmission was not identified in some of these cases but it was presumed to have been close contact leading to skin (10) or nasal (4) colonization and subsequent active infection. In our report, the PVL-producing S. aureus clone was detected in

No.	Family	Sex/ age(y)	a of the outbreak*	Pus cultures	Nasal cultures	PFGE pattern/PVL
1	А	F/33	Periorbital cellulitis	MSSA, Ery/clin- R	MSSA, Ery/clin- R	I/P
2	А	M/36	Leg cellulitis/abscess	None	MSSA, Ery/clin- R	I/P
3	А	M/4	Perianal abscess	MSSA, Ery/clin- R	MSSA, Ery/clin- R	I/P
4	А	F/2	None		N	
5	А	F/1	None		Ν	
6	В	F/37	None		MSSA, Ery/clin-R	I/P
7	В	M/38	None		MSSA, Ery/clin-R	I/P
8	В	M/9	Knee cellulitis/abscess	MSSA, Ery/clin- R	MSSA, Ery/clin- R	I/P
9	В	M/4	Finger-pulp infection	None	MSSA, Ery/clin- S	D/N
10	В	F/3	Lower abdomen cellulitis	None	N	
11	В	F/3	None		Ν	

*PFGE, pulsed-field gel electrophoresis; PVL, Panton-Valentine leukocidin; F, female; MSSA, methicillin-sensitive *Staphylococcus aureus*; Ery, erythromycin; clin, clindamycin; R, resistant; I, identical strain; P, positive; M, male; N, negative; S, sensitive; D, different strain.

LETTERS

nasal cultures in 6 of the 11 members of the 2 families. In this niche, it was able to persist and cause a series of infections in a relatively large number of family members. Even though the S. aureus isolated from active lesions were not available for testing, the recovery of identical PVL-positive organisms from nasal cultures strongly suggests the presence of a pathogenic clone that probably caused the recurrent infections in the 6 affected family members. Our investigation highlights the high transmissibility of this PVL-producing S. aureus clone, its high attack rate, and its virulence. The intervention in this outbreak might have prevented not only subsequent recurrences of cutaneous infections but also further spread of this clone and the manifestation of even more serious infections such as necrotizing pneumonia. Increasing awareness among community-based healthcare providers of PVL-producing S. aureus infections is important to facilitate rapid and adequate response in similar clinical events in the future.

Amos Adler,* Violeta Temper,* Colin S. Block,* Nitsa Abramson,† and Allon E. Moses*

*Hadassah-Hebrew University Medical Center, Jerusalem, Israel; and †Ministry of Health, Jerusalem, Israel

References

- Genestier AL, Michalete MC, Prévoset G, Bellot G, Chalabreysse L, Peyrol S, et al. *Staphylococcus aureus* Panton-Valentine leukocidin directly targets mitochondria and induces Bax-independent apoptosis of human neutrophils. J Clin Invest. 2005;115:3117–27.
- Lina G, Piémont Y, Godail-Gamot F, Bes M, Peter MO, Gauduchon V, et al. Involvement of Panton-Valentine leukocidin–producing *Staphylococcus aureus* in primary skin infections and pneumonia. Clin Infect Dis. 1999;29:1128–32.
- Vandenesch F, Naimi T, Enright MC, Lina G, Nimma GR, Heffernan H, et al. Community-acquired methicillin-resistant *Staphylococcus aureus* carrying Panton-Valentine leukocidin genes: worldwide emergence. Emerg Infect Dis. 2003;9: 978–84.

- Boubaker K, Diebold P, Blanc DS, Vandenesch F, Praz G, Dupuis G, et al. Panton-Valentine leukocidin and staphylococcal skin infections in schoolchildren. Emerg Infect Dis. 2004;10:121–4.
- Österlund A, Kahlmeter G, Bieber L, Runehagen A, Breider JM. Intrafamilial spread of highly virulent *Staphylococcus aureus* strains carrying the gene for Panton-Valentine leukocidin. Scand J Infect Dis. 2002;34:763–87.
- Le Thomas I, Mariani-Kurkdjian P, Collignon A, Gravet A, Clermont O, Brahimi N, et al. Breast milk transmission of a Panton-Valentine leukocidin–producing *Staphylococcus aureus* strain causing infantile pneumonia. J Clin Microbiol. 2001;39:728–9.
- Morreilon P, Que YA, Glauser MP. *Staphylococcus aureus*. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 6th ed. Philadelphia: Elsevier Churchill Livingstone; 2005. p. 2338.
- Maier J, Melzl H, Reischl U, Drubel I, Witte W, Lehn N, et al. Panton-Valentine leukocidin-positive methicillin-resistant *Staphylococcus aureus* in Germany associated with travel or foreign family origin. Eur J Clin Microbiol Infect Dis. 2005;24:637–9.
- Jones TF, Creech CB, Erwin P, Baird SG, Woron AM, Schaffner W. Family outbreaks of invasive community-associated methicillin-resistant *Staphylococcus aureus* infection. Clin Infect Dis. 2006;42:e76–8.
- Begier EM, Frenette K, Barrett NL, Mshar P, Petit S, Boxrud DJ, et al. A high-morbidity outbreak of methicillin-resistant *Staphylococcus aureus* among players on a college football team, facilitated by cosmetic body shaving and turf burns. Clin Infect Dis. 2004;39:1446–53.

Address for correspondence: Allon E. Moses, Department of Clinical Microbiology and Infectious Diseases, Hadassah-Hebrew University Medical Center, Kiryat-Hadassah, Jerusalem, Israel; email: mosesa@md.huji.ac.il



Chikungunya Fever, Hong Kong

To the Editor: Chikungunya virus disease, caused by a mosquitoborne alphavirus, is endemic to Africa and Southeast Asia. It typically causes an acute febrile illness, with joint pain and a skin rash. Chronic arthropathy may develop (1,2). No treatment or vaccine is available, and relatively little research has been conducted into its pathogenesis, compared with that of other arboviruses, such as dengue. Recent reports have described a massive outbreak of chikungunya disease occurring on islands in the Indian Ocean, off the east coast of Africa (1). Reemergence of chikungunya has also been reported from Indonesia (2).

During March 2006, a 66-year-old Chinese man from Hong Kong visited Mauritius where he was bitten by mosquitoes 2 days before returning to Hong Kong. On the return trip, he experienced fever (39°C), severe finger joint and muscle pains, mild headache, and a skin rash, and he sought treatment at the Prince of Wales Hospital (PWH) Infectious Diseases Clinic on the second day of his illness. Physical examination showed a generalized erythematous rash over the trunk and limbs and petechiae over the lower limbs. Mild finger joint stiffness was observed, but no joint swelling. No lymphadenopathy or eschar was detected. Level of C-reactive protein was elevated at 10.4 mg/L. Results of screens for malaria and dengue were negative. Results of other routine assessments were unremarkable. His symptoms subsided gradually within a week.

Serum specimens taken on days 2 and 6 were positive for chikungunya virus RNA by in-house reverse transcription (RT)-PCR at the Public Health Laboratory Service (PHLS) (targeting the nonstructural protein-1 [NSP-1] gene) and PWH laboratory (targeting both NSP-1 and the envelope glycoprotein [E1] gene). An